Clinical Trials in San Antonio

Showing 2641-2660 of 7,028 trials

Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects

NCT02981966

Researchers hope to determine the organ (liver and/or kidney) responsible for the increase in endogenous glucose production (EGP) following the induction of glucosuria (when glucose is excreted in detectable amounts in the urine) with an SGLT2 inhibitor, dapagliflozin.

Diabetes Mellitus, Type 2

The University of Texas Health Science Center at San Antonio32 participantsStarted May 2019

San Antonio, Texas, United States

TERMINATEDPhase 3< 1 mile

Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

NCT05065411

STAGE 1: To determine the safety of enobosarm 9 milligram (mg) once daily (QD) used in combination with a CDK 4/6 inhibitor \[Verzenio® (abemaciclib) tablets, for oral use, 150 mg twice daily (BID)\]. STAGE 2: To demonstrate the efficacy and safety of enobosarm 9 mg QD in combination with abemaciclib 150 mg BID (Enobosarm Combination Group) versus Estrogen Blocking Agent (Control Treatment Group) in the treatment of estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-), androgen receptor positive (AR+) with a AR% nuclei staining ≥40% metastatic breast cancer that have previously experienced disease progression on an estrogen blocking agent plus (palbociclib) as measured by progression free survival (PFS) according to RECIST 1.1 criteria.

Metastatic Breast Cancer

Veru Inc.5 participantsStarted Apr 2022

Chandler, Arizona, United States • Gilbert, Arizona, United States • Tucson, Arizona, United States +27 more locations

Effect of Dapagliflozin on Hepatic and Renal Glucose Metabolism Subjects

Efficacy & Safety Evaluation of Enobosarm in Combo With Abemaciclib in Treatment of ER+HER2- Metastatic Breast Cancer

Find Trials by Condition in San Antonio

Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents (DINAMO)TM

A Study of LY3471851 in Participants With Psoriasis

Phase 3 Study of SNF472 for Calciphylaxis

A Test-Drive Strategy for the Prescription of Prosthetic Feet for People With Leg Amputations

Study Evaluating Safety and Tolerability of Escalating Single and Multiple Doses of PIPE-791 and Food Effect in Healthy Volunteers

HCV-TARGET- Hepatitis C Therapeutic Registry and Research Network

An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis

OCS Lung System EXPAND II Trial

A Study to Compare Bempegaldesleukin (BEMPEG: NKTR-214) Combined With Nivolumab and Tyrosine Kinase Inhibitor (TKI) to Nivolumab and TKI Alone in Participants With Previously Untreated Kidney Cancer That is Advanced or Has Spread

Pilot Immunotherapy Study With Letetresgene Autoleucel (Lete-cel, GSK3377794)T-cells in New York Esophageal Squamous Cell Carcinoma-1 (NY-ESO-1)/ LAGE-1a-positive Advanced Non-small Cell Lung Cancer (NSCLC) Either Alone or in Combination With Pembrolizumab

Development and Testing of a Pediatric Cervical Spine Injury Risk Assessment Tool

Orally Administered ENT-01 for Parkinson's Disease-Related Constipation (KARMET)

A Prospective, Global, Multi-center, Treatment Registry Study of Intravenous Immunoglobulin Maintenance Therapy in Alloantibody Positive Renal Allograft Recipients

A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With Achondroplasia

DS-6157a in Participants With Advanced Gastrointestinal Stromal Tumor (GIST)

A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 (mFOLFOX6) in Gastric/Gastroesophageal Junction Cancer

A Long-Term Safety Trial of LUM-201 in Children With Idiopathic Growth Hormone Deficiency Who Have Previously Completed a LUM-201 Clinical Trial (OraGrowtH211)

Pilot Prospective Study: Long-term Health of Living Kidney Donors